Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1 analog (Wegovy) effects on hepatic fat in adult growth hormone deficiency with obesity
jRCT1031240227Recruiting
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of semaglutide in adult onset growth hormone deficiency (AGHD), obesity and steatosis, sponsored by None. Primary endpoint: Change in hepatic fat content (MRI-PDFF). Started Jul 2024; status: recruiting.
02
Drugs
03
Conditions
adult onset growth hormone deficiency (AGHD)obesitysteatosis
Beyond the preview
Go deeper on jRCT1031240227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240227.